Skip to main content
Article thumbnail
Location of Repository

Antidepressants in the treatment of fibromyalgia

By Chantal Moret and Mike Briley


Fibromyalgia syndrome is a chronic disease of widespread and debilitating pain whose cause is unknown and whose risk factors are poorly understood. It is often comorbid with rheumatoid and other pain disorders as well as psychiatric disorders such as anxiety and depression. Although they are not officially approved for this indication, antiepileptics and antidepressants are often used to treat fibromyalgia. The tricyclic antidepressants (TCAs), particularly amitriptyline, are among the most common treatment strategies. Because of the poor tolerability of the tricyclics, the newer antidepressants have been widely tested in fibromyalgia. The selective serotonin reuptake inhibitors (SSRIs) and the reversible monoamine oxidase inhibitors do not seem to be particularly helpful. The serotonin and norepinephrine reuptake inhibitors (SNRIs), duloxetine and milnacipran, on the other hand, have been shown in placebo-controlled trials to offer significant relief to patients suffering from fibromyalgia. Although no direct comparative studies have been performed, these compounds appear to be as effective as the TCAs but much better tolerated. The effectiveness of the SNRIs as well as other dual acting antidepressants, such as mirtazapine, but not the SSRIs, implies that a dysfunction of both serotonin and norepinephrine neurotransmission probably exists in fibromyalgia. The effectiveness of antidepressants appears to be independent of their effect on comorbid depression

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2002). 57(Suppl 2):61–62.Neuropsychiatric Disease and Treatment 2006:2(4) 548 Moret and Briley Zijlstra TR, Barendregt EJ, van de Laar MA.
  2. (2005). A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment. Ann Readapt Med Phys,
  3. (1998). A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum,
  4. (1986). A double-blind comparison of maprotiline, chloriimipramine and placebo.
  5. (2004). A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
  6. (2000). A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. Arthritis Care Res,
  7. (2005). A new view on hypocortisolism.
  8. (1996). A randomised placebocontrolled trial of sustained release amitriptyline in primary fibromyalgia.
  9. (1995). A randomized controlled trial of citalopram in the treatment of fibromyalgia.
  10. (1986). A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum,
  11. (1996). A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia.
  12. (1998). A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.
  13. (2005). A randomized, doubleblind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
  14. (2002). A randomized, placebocontrolled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia.
  15. (1993). Abnormal responses to electrocutaneous stimulation in fibromyalgia.
  16. (2001). Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome.
  17. (1990). Abnormal transport ratio of serum tryptophan in primary fibromyalgia. Arthritis Rheum,
  18. (2002). Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus.
  19. (2001). Alpha sleep characteristics in fibromyalgia. Arthritis Rheum,
  20. (1998). An open clinical trial of venlafaxine treatment of fibromyalgia.
  21. (2004). An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms.
  22. (2000). Antidepressant treatment of fibromyalgia. A meta-analysis and review.
  23. (1999). Central hyperexcitability in fibromyalgia.
  24. (1992). Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum,
  25. (2001). Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology
  26. (1990). Cerebrospinal fluid monoamines in primary fibromyalgia. Rev Rhum Mal Osteoartic,
  27. (2000). Citalopram in patients with fibromyalgia— a randomized, double-blind, placebo-controlled study.
  28. (2001). Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep,
  29. (2004). Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol,
  30. (1991). Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials.
  31. (1992). Comorbidity of fibromyalgia with medical and psychiatric disorders.
  32. (1994). Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum,
  33. (2006). Complementary and alternative medical therapies in fibromyalgia.
  34. (2002). Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum, 46:845– 7. Crofford LJ.
  35. (1990). Criteria for the Classification of Fibromyalgia.
  36. (2005). Current trends in neuropathic pain treatments with special reference to fibromyalgia.
  37. (2002). Descending control of pain.
  38. (1987). Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome.
  39. (1995). Effect of p-chlorophenylalanine and alpha-methyltyrosine on the antinociceptive effect of antidepressant drugs. Pharmacol Toxicol,
  40. (1999). Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity.
  41. (2005). Efficacy of milnacipran in patients with fibromyalgia.
  42. (1999). Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc,
  43. (1978). Endogenous pain control mechanisms: review and hypothesis.
  44. (1984). Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann Rev Neurosci,
  45. (1986). Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study.
  46. (2005). Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain.
  47. (2000). Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med,
  48. (2003). Experimental evaluation of an altered tryptophan metabolism in fibromyalgia. Adv Exp Med Biol,
  49. (2004). Family study of fibromyalgia.
  50. (1985). Fibromyalgia and major affective disorder: a controlled phenomenology and family history study.
  51. (1996). Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol,
  52. (1995). Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum,
  53. (2001). Fibromyalgia syndrome and serotonin. Clin Exp Rheumatol,
  54. (2003). Fibromyalgia syndrome: an overview of potential drug targets.
  55. (2005). Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.
  56. (2006). Fibromyalgia syndrome: which antidepressant drug should we choose? Curr Pharm Des,
  57. (2003). Fibromyalgia— from syndrome to disease. Overview of pathogenetic mechanisms.
  58. (2005). Fibromyalgia: present to future. Curr Rheumatol Rep,
  59. (2002). Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum,
  60. (1994). Fluoxetine combined with cyclobenzaprine in the treatment of fibromyalgia,
  61. (2002). Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum,
  62. (1998). Genetic factors in fibromyalgia syndrome.
  63. (2005). Genetic factors in neuromuscular pain.
  64. (2002). Hypersomnolence in fibromyalgia syndrome. Clin Exp Rheumatol,
  65. (2004). Hypothalamic-pituitary-gonadal axis and cortisol in young women with primary fibromyalgia: the potential roles of depression, fatigue, and sleep disturbance in the occurrence of hypocortisolism.
  66. (2005). Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum,
  67. (1989). Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline.
  68. (2002). Is fibromyalgia a neurologic disease? Curr Pain Headache Rep,
  69. (2006). Is there a role for cytokine based therapies in fibromyalgia? Curr Pharm Des,
  70. (2006). Major depression, fibromyalgia and labour force participation: a population-based cross-sectional study.
  71. (2004). Management of fibromyalgia syndrome.
  72. (1999). Management of fibromyalgia.
  73. (2005). Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother,
  74. (1975). Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med,
  75. (2000). Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am,
  76. (2002). Norepinephrineevoked pain in fibromyalgia. A randomized pilot study.
  77. (2004). Open trial of mirtazapine in patients with fibromyalgia.
  78. (2002). Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology
  79. (1991). Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients.
  80. (2003). Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing.
  81. (2006). Peripheral and central contributions to hyperalgesia in irritable bowel syndrome.
  82. (1992). Plasma and urinary catecholamines in primary fibromyalgia: a controlled study.
  83. (1992). Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome.
  84. (1999). Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum,
  85. (2004). Predictors of response to placebo-controlled, double-blind trial of paroxetine controlled release in fibromyalgia. Program and abstracts of the American Psychiatric Association Annual Meeting;
  86. (2005). Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
  87. (1993). Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum,
  88. (2006). Prevalence of irritable bowel syndrome and depression in fibromyalgia.
  89. (2006). Prevalence, comorbidity and impact of irritable bowel syndrome in Norway.
  90. (1999). Psychiatric disorders in patients with fibromyalgia. A multicenter investigation.
  91. (2002). Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am,
  92. (2004). Reboxetine: a norepinephrine selective reuptake pump inhibitor.
  93. (1999). Reduced hypothalamicpituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome.
  94. (1994). Report of the Multicenter Criteria Committee. Arthritis Rheum,
  95. (2000). Responsiveness of fibromyalgia clinical trial outcome measures.
  96. (1994). Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem,
  97. (1989). Serum amino acids in fibrositis/fibromyalgia syndrome.
  98. (1998). Skeletal muscle abnormalities in patients with fibromyalgia.
  99. (2003). Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome.
  100. (1990). The analgesic effect of tricyclic antidepressants.
  101. (2002). The development of widespread pain after injuries.
  102. (2002). The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med,
  103. (1991). The fibromyalgia impact questionnaire: development and validation.
  104. (2006). The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes.
  105. (2004). The management of fibromyalgia.
  106. (1993). The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res,
  107. (2002). The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull,
  108. (1996). The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am,
  109. (1998). Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo.
  110. (2000). Treatment of fibromyalgia with antidepressants: a meta-analysis.
  111. (2004). Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis.
  112. (2000). Venlafaxine and fibromyalgia.
  113. (2003). Venlafaxine treatment of fibromyalgia.
  114. (2000). Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.